Why the study?
Does dabigatran or rivaroxaban improve efficacy and safety compared to enoxaparin for thromboprophylaxis in patients undergoing hip or knee arthroplasty?
Population
18,405 participants undergoing hip or knee arthroplasty (pooled from 6 phase III randomized trials)
Comparison
Dabigatran or rivaroxaban vs Enoxaparin (40 mg once daily or 30 mg twice daily)
Design
Meta-analysis
Authors
Loading...
Rivaroxaban improves VTE prevention over enoxaparin at higher bleeding cost while dabigatran matches enoxaparin; confirms NOAC-specific trade-offs for arthroplasty thromboprophylaxis.
Does dabigatran or rivaroxaban improve efficacy and safety compared to enoxaparin for thromboprophylaxis in patients undergoing hip or knee arthroplasty?
In patients undergoing major joint arthroplasty, rivaroxaban is more effective than enoxaparin but carries a higher bleeding risk, whereas dabigatran and enoxaparin have similar efficacy and safety profiles.
Huisman et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: